Table 7.
Effect of cross-reactivity on the proportion of women with positive and false-positive HPV test results
| HC2 | cobas | APTIMA | ||||
|---|---|---|---|---|---|---|
| N (%) | ≥CIN2 | N (%) | ≥CIN2 | N (%) | ≥CIN2 | |
| Primary screening, 30–65 years (n = 2859) | ||||||
| All positive test results | 335 (11.7 %) | 46 | 464 (16.2 %) | 49 | 270 (9.4 %) | 46 |
| Samples with high-risk genotypes | 262 (9.2 %) | 45 | 357 (12.5 %) | 48 | 221 (7.7 %) | 45 |
| Cross-reacting samples | 73 (2.6 %) | 1 | 107 (3.7 %) | 1 | 49 (1.7 %) | 1 |
| False-positive test results, all (%) | 289 (10.1 %) | – | 415 (14.5 %) | – | 224 (7.8 %) | – |
| False-positive test results, after exclusion of cross-reactivity (%) | 217 (7.6 %) | – | 309 (10.8 %) | – | 176 (6.2 %) | – |
| Proportion of false-positive test results due to cross-reactivity | 25 % | – | 26 % | – | 21 % | – |
| Referral population (n = 887) | ||||||
| All positive test results | 401 (45.2 %) | 124 | 453 (51.1 %) | 123 | 332 (37.4 %) | 112 |
| Samples with high-risk genotypes | 345 (38.9 %) | 117 | 410 (46.2 %) | 120 | 316 (35.6 %) | 109 |
| Cross-reacting samples | 56 (6.3 %) | 7 | 43 (4.8 %) | 3 | 16 (1.8 %) | 3 |
| False-positive test results, all (%) | 277 (31.2 %) | – | 330 (37.2 %) | – | 220 (24.8 %) | – |
| False-positive test results, after exclusion of cross-reactivity (%) | 228 (25.7 %) | – | 290 (32.7 %) | – | 207 (23.3 %) | – |
| Proportion of false-positive test results due to cross-reactivity | 18 % | – | 12 % | – | 6 % | – |